KARADURMUŞ, N. Et Al. 2019. Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients. journal of oncological scinece .

KARADURMUŞ, N., ŞENDUR, M. A. N., KARACA, Ş. B., ÖLMEZ, Ö. F., HACIBEKİROĞLU, İ., COŞKUN, H. Ş., ... DEĞİRMENCİOĞLU, S.(2019). Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients. journal of oncological scinece .

KARADURMUŞ, NURİ Et Al. "Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients," journal of oncological scinece , 2019

KARADURMUŞ, NURİ Et Al. "Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients." journal of oncological scinece , 2019

KARADURMUŞ, N. Et Al. (2019) . "Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients." journal of oncological scinece .

@article{article, author={NURİ KARADURMUŞ Et Al. }, title={Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients}, journal={journal of oncological scinece}, year=2019}